PTC Therapeutics Inc’s filing revealed that its CHIEF FINANCIAL OFFICER Gravier Pierre unloaded Company’s shares for reported $0.12 million on Jul 15 ’25. In the deal valued at $49.46 per share,2,516 shares were sold. As a result of this transaction, Gravier Pierre now holds 71,920 shares worth roughly $3.76 million.
Then, Gravier Pierre bought 2,516 shares, generating $124,435 in total proceeds.
Before that, Boulding Mark Elliott sold 1,929 shares. PTC Therapeutics Inc shares valued at $89,081 were divested by the EXEC. VP AND CLO at a price of $46.18 per share. As a result of the transaction, Boulding Mark Elliott now holds 103,901 shares, worth roughly $5.43 million.
Truist initiated its PTC Therapeutics Inc [PTCT] rating to a Buy in a research note published on June 17, 2025; the price target was $80. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in early May from “a Neutral” to “a Buy”. Citigroup also remained covering PTCT and has increased its forecast on May 07, 2025 with a “Neutral” recommendation from previously “Sell” rating. BofA Securities revised its rating on March 11, 2025. It rated PTCT as “a Neutral” which previously was an “an Underperform”.
Price Performance Review of PTCT
On Monday, PTC Therapeutics Inc [NASDAQ:PTCT] saw its stock jump 0.23% to $52.25. Over the last five days, the stock has gained 17.84%. PTC Therapeutics Inc shares have risen nearly 54.36% since the year began. Nevertheless, the stocks have risen 15.75% over the past one year.
How much short interest is there in PTC Therapeutics Inc?
A steep rise in short interest was recorded in PTC Therapeutics Inc stocks on 2025-07-15, growing by 0.7 million shares to a total of 5.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 5.07 million shares. There was a rise of 12.13%, which implies that there is a positive sentiment for the stock.
